Cyramza

Monotherapy or in combination w/ paclitaxel for adult patients w/ advanced or metastatic, gastric or gastro-oesophageal junction adenocarcinoma (GEJ) w/ disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. In combination w/ erlotinib for 1st-line treatment of adult patients w/ metastatic NSCLC w/ activating epidermal growth factor receptor (EGFR) mutations. In combination w/ docetaxel for adult patients w/ locally advanced or metastatic NSCLC w/ disease progression on or after platinum-based chemotherapy. In combination w/ FOLFIRI (irinotecan, folinic acid & 5-fluorouracil) for adult patients w/ metastatic CRC w/ disease progression on or after prior therapy w/ bevacizumab, oxaliplatin & fluoropyrimidine. Adult patients w/ advanced or unresectable hepatocellular carcinoma (HCC) w/ serum α-fetoprotein (AFP) of ≥400 ng/mL & those previously treated w/ sorafenib.

IV Max infusion rate: 25 mg/min. Gastric cancer & GEJ adenocarcinoma Monotherapy: 8 mg/kg every 2 wk. Combination therapy w/ paclitaxel: 8 mg/kg on days 1 & 15 of a 28-day cycle, prior to paclitaxel 80 mg/m² infusion over 60 min on days 1, 8 & 15 of a 28-day cycle. NSCLC w/ activating EGFR mutations Combination therapy w/ erlotinib: 10 mg/kg every 2 wk. NSCLC after platinum-based chemotherapy Combination therapy w/ docetaxel: 10 mg/kg on day 1 of a 21-day cycle, prior to docetaxel 75 mg/m² infusion over 60 min on day 1 of a 21-day cycle. CRC 8 mg/kg infusion every 2 wk prior to FOLFIRI administration. HCC 8 mg/kg as single agent every 2 wk. AFP testing in HCC Select patient based on serum AFP conc of ≥400 ng/mL w/ a validated AFP test prior to treatment.

Hypersensitivity. Tumour cavitation or involvement of major vessels in patients w/ NSCLC.

Targeted Cancer Therapy

L01FG02 - ramucirumab ; Belongs to the class of VEGF/VEGFR (Vascular Endothelial Growth Factor / Receptors) inhibitors. Used in the treatment of cancer.

POM